BAYER HLTHCARE FDA Approval NDA 019847

NDA 019847

BAYER HLTHCARE

FDA Drug Application

Application #019847

Documents

Letter2000-08-30
Letter2002-04-17
Letter2004-03-28
Letter2004-07-21
Letter2005-01-11
Letter2005-11-18
Letter2008-10-07
Letter2009-02-18
Letter2009-05-07
Letter2009-06-30
Letter2011-08-08
Letter2013-01-31
Letter2015-02-12
Letter2015-03-20
Letter2016-07-26
Label2004-04-05
Label2004-07-21
Label2005-01-11
Label2005-11-17
Label2009-02-20
Label2011-03-04
Label2011-08-16
Label2011-11-04
Label2015-03-02
Label2015-03-20
Letter2004-07-21
Letter2004-07-21
Letter2005-05-20
Letter2006-06-28
Letter2007-07-05
Letter2008-01-24
Letter2011-11-21
Letter2011-03-02
Letter2011-08-15
Letter2011-10-20
Letter2013-08-16
Review2008-08-08
Review2000-08-30
Review2008-08-04
Review2008-07-31
Review2008-07-31
Review2007-07-09
Label2000-08-30
Label2002-04-17
Label2004-07-21
Label2004-07-21
Label2005-05-20
Label2007-06-27
Label2008-01-23
Label2008-10-09
Label2009-05-11
Label2011-11-16
Label2013-02-01
Label2013-08-15
Label2016-07-26
Review2008-08-11
Review2008-07-31
Review2008-07-31
Medication Guide2011-03-15
Label2017-07-31
Letter2017-08-02
Letter2018-10-23
Label2018-10-29
Medication Guide2018-10-29
Letter2019-05-06
Label2019-05-07
Medication Guide2019-05-07
Letter2020-03-06
Label2020-03-09
Medication Guide2020-03-09
Letter2020-05-11
Label2020-05-11
Medication Guide2020-05-11
Label2022-03-28
Medication Guide2022-03-28
Letter2022-03-28

Application Sponsors

NDA 019847BAYER HLTHCARE

Marketing Status

Discontinued001
Discontinued002
Discontinued003

Application Products

001INJECTABLE;INJECTION400MG/40ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**1CIPROCIPROFLOXACIN
002INJECTABLE;INJECTION200MG/20ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**1CIPROCIPROFLOXACIN
003INJECTABLE;INJECTION1200MG/120ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**0CIPROCIPROFLOXACIN

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP1990-12-26STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL3AP1992-05-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL4AP1992-04-23STANDARD
LABELING; LabelingSUPPL5AP1995-10-25
MANUF (CMC); Manufacturing (CMC)SUPPL7AP1993-02-12STANDARD
EFFICACY; EfficacySUPPL8AP1996-10-21UNKNOWN
MANUF (CMC); Manufacturing (CMC)SUPPL9AP1993-06-14STANDARD
EFFICACY; EfficacySUPPL10AP1996-10-10STANDARD
LABELING; LabelingSUPPL12AP1997-09-26STANDARD
EFFICACY; EfficacySUPPL13AP1998-04-03UNKNOWN
LABELING; LabelingSUPPL14AP1996-08-09STANDARD
EFFICACY; EfficacySUPPL15AP1997-08-07STANDARD
EFFICACY; EfficacySUPPL16AP1998-09-24STANDARD
LABELING; LabelingSUPPL17AP1998-09-24STANDARD
EFFICACY; EfficacySUPPL18AP1998-09-24STANDARD
LABELING; LabelingSUPPL20AP1998-09-24STANDARD
LABELING; LabelingSUPPL21AP2000-06-28STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL22AP1999-11-01STANDARD
EFFICACY; EfficacySUPPL24AP2000-08-30PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL25AP2000-10-31STANDARD
LABELING; LabelingSUPPL26AP2002-04-17
EFFICACY; EfficacySUPPL27AP2004-03-25PRIORITY
LABELING; LabelingSUPPL28AP2004-07-14STANDARD
LABELING; LabelingSUPPL29AP2004-07-14STANDARD
EFFICACY; EfficacySUPPL30AP2005-01-07UNKNOWN
LABELING; LabelingSUPPL31AP2004-07-14STANDARD
LABELING; LabelingSUPPL32AP2005-05-18STANDARD
LABELING; LabelingSUPPL36AP2005-11-09STANDARD
LABELING; LabelingSUPPL37AP2006-06-19STANDARD
LABELING; LabelingSUPPL39AP2007-06-25STANDARD
LABELING; LabelingSUPPL41AP2008-01-18STANDARD
LABELING; LabelingSUPPL42AP2008-10-03STANDARD
LABELING; LabelingSUPPL43AP2009-02-13STANDARD
LABELING; LabelingSUPPL44AP2009-04-27STANDARD
LABELING; LabelingSUPPL45AP2009-06-24STANDARD
LABELING; LabelingSUPPL46AP2011-11-15STANDARD
LABELING; LabelingSUPPL47AP2011-02-25901 REQUIRED
LABELING; LabelingSUPPL50AP2011-08-12UNKNOWN
REMS; REMSSUPPL51AP2011-08-03N/A
LABELING; LabelingSUPPL52AP2011-10-18UNKNOWN
LABELING; LabelingSUPPL53AP2013-01-30STANDARD
LABELING; LabelingSUPPL54AP2013-08-14901 REQUIRED
EFFICACY; EfficacySUPPL55AP2015-02-02STANDARD
LABELING; LabelingSUPPL56AP2015-03-19STANDARD
LABELING; LabelingSUPPL57AP2016-07-26STANDARD
LABELING; LabelingSUPPL58AP2017-07-28STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL59AP2018-10-18STANDARD
LABELING; LabelingSUPPL60AP2019-05-03STANDARD
LABELING; LabelingSUPPL61AP2020-03-05STANDARD
LABELING; LabelingSUPPL62AP2020-05-08STANDARD
LABELING; LabelingSUPPL63AP2022-03-25STANDARD

Submissions Property Types

SUPPL1Null0
SUPPL3Null0
SUPPL4Null0
SUPPL7Null0
SUPPL9Null0
SUPPL22Null0
SUPPL24Null41
SUPPL25Null0
SUPPL28Null0
SUPPL29Null9
SUPPL44Null7
SUPPL46Null15
SUPPL47Null6
SUPPL50Null7
SUPPL51Null7
SUPPL52Null15
SUPPL53Null15
SUPPL54Null6
SUPPL55Null7
SUPPL56Null7
SUPPL57Null7
SUPPL58Null15
SUPPL59Null6
SUPPL60Null6
SUPPL61Null7
SUPPL62Null7
SUPPL63Null15

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 19847
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.